tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2013 Dec 30;10(3). [Epub ahead of print]
Bringing influenza vaccines into the 21st century.
Settembre EC, Dormitzer PR, Rappuoli R.
Author information
Abstract
The recent H7N9 influenza outbreak in China highlights the need for influenza vaccine production systems that are robust and can quickly generate substantial quantities of vaccines that target new strains for pandemic and seasonal immunization. Although the influenza vaccine system, a public-private partnership, has been effective in providing vaccines, there are areas for improvement. Technological advances such as mammalian cell culture production and synthetic vaccine seeds provide a means to increase the speed and accuracy of targeting new influenza strains with mass-produced vaccines by dispensing with the need for egg isolation, adaptation, and reassortment of vaccine viruses. New influenza potency assays that no longer require the time-consuming step of generating sheep antisera could further speed vaccine release. Adjuvants that increase the breadth of the elicited immune response and allow dose sparing provide an additional means to increase the number of available vaccine doses. Together these technologies can improve the influenza vaccination system in the near term. In the longer term, disruptive technologies, such as RNA-based flu vaccines and 'universal' flu vaccines, offer a promise of a dramatically improved influenza vaccine system.
KEYWORDS:
RNA-based, cell culture, iInfluenza, potency assay, synthetic seed, vaccine
PMID:
24378716
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24378716
Bringing influenza vaccines into the 21st century.
Settembre EC, Dormitzer PR, Rappuoli R.
Author information
Abstract
The recent H7N9 influenza outbreak in China highlights the need for influenza vaccine production systems that are robust and can quickly generate substantial quantities of vaccines that target new strains for pandemic and seasonal immunization. Although the influenza vaccine system, a public-private partnership, has been effective in providing vaccines, there are areas for improvement. Technological advances such as mammalian cell culture production and synthetic vaccine seeds provide a means to increase the speed and accuracy of targeting new influenza strains with mass-produced vaccines by dispensing with the need for egg isolation, adaptation, and reassortment of vaccine viruses. New influenza potency assays that no longer require the time-consuming step of generating sheep antisera could further speed vaccine release. Adjuvants that increase the breadth of the elicited immune response and allow dose sparing provide an additional means to increase the number of available vaccine doses. Together these technologies can improve the influenza vaccination system in the near term. In the longer term, disruptive technologies, such as RNA-based flu vaccines and 'universal' flu vaccines, offer a promise of a dramatically improved influenza vaccine system.
KEYWORDS:
RNA-based, cell culture, iInfluenza, potency assay, synthetic seed, vaccine
PMID:
24378716
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24378716